You are here: Industry Insights > SARS-CoV-2

News List

Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine prnewswire
October 21, 2021
FinancialNewsMedia.com News Commentary - Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing SARS-CoV-2, as well as other coronaviruses...
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates prnewswire
October 13, 2021
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need...
BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission prnasia
October 13, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission.
Host Genetic Backgrounds Underlie Variable COVID-19 Pathology prnewswire
September 28, 2021
Since the advent of the COVID-19 pandemic, tremendous progress has been made in developing effective vaccines against SARS-CoV-2, the coronavirus that causes COVID-19, and in treating ill patients.
/C O R R E C T I O N -- pHOXBIO/ prnasia
September 28, 2021
In the news release, pHOXBIO Announces Breakthrough Clinical Trial Results Concluding Prophylactic Nasal Spray Prevents Infection from SARS-CoV-2, issued Sept. 22, 2021 by pHOXBIO...
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins prnasia
September 28, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study...
Nature Scientific Reports publishes novel AI technique that can automatically detect poor-quality medical data and improve healthcare AI and data privacy prnasia
September 13, 2021
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore...
DiaCarta Receives CE/IVD for its New COVID 19 Screening Test that Identifies Delta Plus and New Variants prnasia
September 13, 2021
DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore...
A Third of Americans Were Infected With COVID-19 in 2020: Study drugs
August 27, 2021
One-third of the U.S. population -- about 103 million people -- had been infected by the SARS-CoV-2 virus by the end of 2020, but more than three-quarters of the cases weren't officially confirmed, according to a Columbia University study.
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern firstwordpharma
August 27, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System ("TAMUS") of its exercise of the option to an exclusive license for the global development and commercialization of highly potent

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page